Search Results - "Mannaerts, B. M."

A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol by Devroey, P., Boostanfar, R., Koper, N.P., Mannaerts, B.M.J.L., IJzerman-Boon, P.C., Fauser, B.C.J.M.

“…BACKGROUND Corifollitropin alfa, a fusion protein lacking LH activity, has a longer elimination half-life and extended time to peak levels than recombinant FSH…”
Get full text

Induction of Multiple Follicular Development by a Single Dose of Long-Acting Recombinant Follicle-Stimulating Hormone (FSH-CTP, Corifollitropin Alfa) for Controlled Ovarian Stimulation before in Vitro Fertilization by Devroey, P., Fauser, B. C., Platteau, P., Beckers, N. G., Dhont, M., Mannaerts, B. M.

“…In a first feasibility study, the efficacy and safety of a single dose of recombinant long-acting FSH (FSH-CTP) were investigated in in vitro fertilization…”
Get full text

Pharmacodynamics of a Single Low Dose of Long-Acting Recombinant Follicle-Stimulating Hormone (FSH-Carboxy Terminal Peptide, Corifollitropin Alfa) in Women with World Health Organization Group II Anovulatory Infertility by Balen, A. H., Mulders, A. G., Fauser, B. C., Schoot, B. C., Renier, M. A., Devroey, P., Struijs, M. J., Mannaerts, B. M.

“…In a double-blind, placebo-controlled, randomized study, 55 anovulatory subjects received a single sc injection of placebo (n = 10) or recombinant long-acting…”
Get full text

Kisspeptin treatment induces gonadotropic responses and rescues ovulation in a subset of preclinical models and women with polycystic ovary syndrome by Romero-Ruiz, A, Skorupskaite, K, Gaytan, F, Torres, E, Perdices-Lopez, C, Mannaerts, B M, Qi, S, Leon, S, Manfredi-Lozano, M, Lopez-Rodriguez, C, Avendaño, M S, Sanchez-Garrido, M A, Vazquez, M J, Pinilla, L, van Duin, M, Kohout, T A, Anderson, R A, Tena-Sempere, M

“…Abstract STUDY QUESTION Can kisspeptin treatment induce gonadotrophin responses and ovulation in preclinical models and anovulatory women with polycystic ovary…”
Get full text

Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency by Fauser, B.C.J.M., Mannaerts, B.M.J.L., Devroey, P., Leader, A., Boime, I., Baird, D.T.

“…BACKGROUND Recombinant DNA technologies have been used to develop longer-acting therapeutic proteins. One approach is to introduce sequences containing…”
Get full text

High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization by de Jong, D, Macklon, N S, Mannaerts, B M, Coelingh Bennink, H J, Fauser, B C

“…This case report describes the first attempt to treat imminent ovarian hyperstimulation syndrome (OHSS) by using a gonadotrophin-releasing hormone (GnRH)…”
Get full text

Dose Selection of Corifollitropin Alfa by Modeling and Simulation in Controlled Ovarian Stimulation by Greef, R, Zandvliet, A S, Haan, A F J, IJzerman‐Boon, P C, Marintcheva‐Petrova, M, Mannaerts, B M J L

“…In controlled ovarian stimulation (COS), a single subcutaneous dose of corifollitropin alfa is used to initiate and sustain multifollicular growth for 7 days…”
Get full text

A randomized three-way cross-over study in healthy pituitary-suppressed women to compare the bioavailability of human chorionic gonadotrophin (Pregnyl) after intramuscular and subcutaneous administration by Mannaerts, B M, Geurts, T B, Odink, J

“…The objective of this study was to compare the bioavailability of s.c. and i.m. administration of human chorionic gonadotrophin (HCG; Pregnyl). In a…”
Get full text

LH suppression following different low doses of the GnRH antagonist ganirelix in polycystic ovary syndrome by Hohmann, F P, Laven, J S E, Mulders, A G M G J, Oberyé, J J L, Mannaerts, B M J L, de Jong, F H, Fauser, B C J M

“…Elevated LH concentration is a common feature in polycystic ovary syndrome (PCOS). This study was designed to establish whether elevated LH levels in PCOS…”
Get full text

Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers by Oberyé, J J, Mannaerts, B M, Huisman, J A, Timmer, C J

“…To assess the dose-proportionality and pharmacodynamic properties of multiple doses of ganirelix (Antagon/Orgalutran; NV Organon, Oss, the Netherlands)…”
Get more information

Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers by Oberyé, J J, Mannaerts, B M, Kleijn, H J, Timmer, C J

“…To assess the absolute bioavailability of ganirelix (Antagon/Orgalutran; NV Organon, Oss, the Netherlands) after a single SC injection. Randomized, crossover,…”
Get more information

Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins by Out, H J, Driessen, S G, Mannaerts, B M, Coelingh Bennink, H J

“…To assess ongoing pregnancy rates (PRs) in IVF after treatment with recombinant FSH (follitropin beta, Puregon; NV Organon, Oss, The Netherlands) as compared…”
Get more information

A dose proportionality study of subcutaneously and intramuscularly administered recombinant human follicle-stimulating hormone (Follistim/Puregon) in healthy female volunteers by Voortman, G, Mannaerts, B M, Huisman, J A

“…To assess pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneous (s.c.) administration of recombinant FSH in comparison with the intramuscular (i.m.)…”
Get more information

P–587 Highly purified human menopausal gonadotrophin (HP-hMG, Menopur) as a ready-to-use solution for injection in pre-filled pen is bioequivalent to HP-hMG powder for reconstitution by Jonker, D M, Koch, M, Larsson, P, Ravi, A, Rasmussen, B B, Speer, R, Mannaerts, B M J L

“…Abstract Study question Are serum FSH levels after single subcutaneous dosing of HP-hMG in a liquid formulation and a powder formulation bioequivalent? Summary…”
Get full text

Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol by Broekmans, Frank J, Verweij, Pierre J M, Eijkemans, Marinus J C, Mannaerts, Bernadette M J L, Witjes, Han

“…Can predictors of low and high ovarian responses be identified in patients undergoing controlled ovarian stimulation (COS) in a GnRH antagonist protocol?…”
Get full text

Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacy by Mannaerts, BMJL, Rombout, F, Out, HJ, Bennink, HC

“…Single-dose and multiple-rising dose studies of recombinant follicle stimulating hormone (rFSH) in hypogonadotrophic male and female volunteers demonstrated…”
Get full text

Sister chromatid exchanges in calves with hereditary zinc deficiency (lethal trait A 46) by Bosma, A A, Mannaerts, B M, de Haan, N A, Kroneman, J

“…Frequencies of sister chromatid exchanges (SCEs) in cultured blood lymphocytes are rather lower than higher in calves with hereditary zinc deficiency (lethal…”
Get more information

A randomized dose–response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation

“…BACKGROUND This study primarily investigated the dose–response relationship of corifollitropin alfa to initiate multifollicular development for the first 7…”
Get full text

A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol by Devroey, P., Boostanfar, R., Koper, N.P., Mannaerts, B.M.J.L., Verweij, P.J.M., Stegmann, B.J., IJzerman-Boon, P.C., Fauser, B.C.J.M.

Get full text

Recombinant human follicle-stimulating hormone and ovarian response in gonadotrophin-deficient women by Schoot, D C, Harlin, J, Shoham, Z, Mannaerts, B M, Lahlou, N, Bouchard, P, Bennink, H J, Fauser, B C

“…Seven women suffering from hypogonadism due to previous hypophysectomy, isolated gonadotrophin deficiency, or Kallman's syndrome [median age 39 years (range…”
Get more information